Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.
FORE Biotherapeutics’s Plixorafenib (PLX-8394) is a next-generation, orally selective inhibitor and specific dimer breaker of BRAF protein under clinical development. Its favorable efficacy and tolerability are updated in the recently presented phase 1/2a results in BRAF V600 advanced solid tumors. Plixorafenib was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF. It has been granted Fast Track Designation and Orphan Drug Designation from the U.S. FDA.